Pfizer Inc. (NYSE: PFE) announced today that it has entered into a new supply agreement with the US government to support the ongoing COVID-19 fight. The agreement calls for the US government to receive 105 million doses in three different dosages (30 µg, 10 µg and 3 µg). Adult Omicron-adapted COVID-19 vaccinations may be included. The Food and Drug Administration in the United States must approve this. After receiving the first 105 million doses, the US government will pay the companies $3.2 billion. The agreement allows the US government to purchase additional doses worth up to 195 million dollars, bringing the total number of possible doses to 300 million.
According to Albert Bourla, Chairman and Chief Executive Officer of Pfizer, the new agreement will allow people to have access to vaccines in the country as the virus evolves. “Vaccines are critical for protecting everyone against COVID-19.” We are proud of our long-term collaboration with the US government in combating this pandemic. It will contain an Omicron-specific vaccine. This is essential in order to combat the rapidly spreading Omicron variant.” We are grateful for the US government’s continued support in our shared goal of bringing this pandemic to an end.” On June 25, 2022, Pfizer and BioNTech shared critical data demonstrating the safety, tolerability, and immunogenicity of two Omicron-matched vaccine candidates. This data is shared with FDA regulators and has been filed for the United States. An emergency permit is planned. After approval or approval from the US Centers for Disease Control and Prevention (CDC) and subsequent recommendations, the company has begun manufacturing risky Omicron customized vaccine candidates for immediate shipment.
When received and according to the instructions of the U.S. government. In accordance with the U.S. government’s commitment to providing free COVID-19 vaccines, all eligible U.S. citizens will receive the vaccine at no cost. Pfizer and BioNTech created the Pfizer BioNTech CoVID-19 Vaccine based upon BioNTech’s proprietary mRNA tech. BioNTech holds the United States Marketing Authorization Holder. It also holds authorizations for Canada, United Kingdom and Canada. It also holds emergency authorizations or equivalents to the United States (jointly with Pfizer), and other countries. Submissions are being made for regulatory approvals in countries where emergency authorizations/equivalents were initially granted.
I love to come up with new ideas that help website with their SEO in a healthy way. I like posting information and knowledge on multiple topics with an objective to create online visibility as well as share his inputs. Apart from this I am also interested in Reading books, sports and music.